财联社记者查询后发现，5月11日广州公共资源交易中心发布《关于公布各批次集采中选药品合同签订和供应情况的通知》，截至4月30日各批次集采中选药品未建立配送关系及配送率较低企业列表中，亚宝药业均在其列。公告显示，广东联盟阿莫西林等药品集中带量采购中，亚宝药业甲钴胺片（规格：0.5mg）配送率为0%，另外，在河南十四省集采中选后，公司曲克芦丁片配送率仅为7%。① Yabao Pharmaceutical revealed that the distribution rate of methcobalamin was 0% after winning the bid for drugs such as amoxicillin in Guangdong Province. After verification, the licensing period for the drug had not yet begun; ② Company director Ren Beng revealed that in the future, products such as Honghua injection, Qingkailing injection, and Chaihu injection will also actively participate in the collection; ③ The company's innovative drug development progress has attracted much attention.
Financial Services Association, May 28 (Reporter He Fan) After Yabao Pharmaceutical (600351.SH) methylcobalamin products were revealed to have won the bid for amoxicillin and other drugs in Guangdong Province, the delivery rate was 0%? After investigation by a reporter from the Financial Federation, I learned that in fact, the licensing period for this drug has not yet begun. In addition, during the performance meeting, company director Ren Fengbo revealed to the Financial Federation reporter that future products such as safflower injection and Qingkailing injection will also actively participate in the collection. On the other hand, the company's innovative drug development progress is also a topic that investors are concerned about.
Recently, media reports have reported that there is a problem of inadequate distribution of collected drugs in Guangzhou. Among the product regulations with a distribution rate of less than 30%, more than 65% of the product regulations have a direct delivery rate of 0%, and the winning bidder companies have no supply at all. Drugs with a 0% distribution rate in the table attached to the article include Yabao Pharmaceutical's methylcobalamin.
After an inquiry, a reporter from the Financial Services Association discovered that on May 11, the Guangzhou Public Resources Exchange Center issued the “Notice on Announcing the Contract Signing and Supply Status of Selected Drugs in Each Batch”. As of April 30, Yabao Pharmaceutical was on the list of companies that had not established distribution relationships and had low delivery rates for selected drugs collected in each batch. According to the announcement, in the centralized procurement of drugs such as amoxicillin by the Guangdong Union, the distribution rate of Yabao Pharmaceutical's methylcobalamin tablets (specification: 0.5mg) was 0%. Furthermore, after being collected and selected in 14 provinces in Henan, the company's troxerutin tablet delivery rate was only 7%.
At the results meeting, Ren Pengbo responded to the Financial Federation reporter that the sales revenue of methylcobalamin tablets in 2023 was more than 90 million yuan, and the issue of a 0% distribution rate still needs to be further verified. However, when the Financial Services Association reporter wanted to know more about the situation, the company declined to respond for reasons such as “the content of the question may have involved typos” and “other investors have already asked the same question.”
Afterwards, the Financial Services Association reporter called Yabao Pharmaceutical as an investor. The company's securities department staff said that the data on the table was up to April 30. According to information, the company's methylcobalamin products began to be implemented in May, so there is no data on the table, but it's unclear why they are listed. At the same time, it believes that the lower distribution rate of troxerutin tablets may be due to the fact that collection and execution in the 14 provinces of Henan did not take a long time, and it will increase one after another later, while troxerutin sales account for less of the company's total revenue, so there is little impact.
In fact, according to the official website of the Guangdong Health Insurance Administration, according to the “Guangdong Alliance Centralized Volume Procurement Documents for Amoxicillin and Other Drugs”, the procurement period for the drugs collected this time ends on December 31, 2025, and the first year's procurement period is from May 1, 2024 to December 31, 2024.
Industry expert Li Changcheng analyzed to the Financial Federation reporter that during the collection, the quantity of common, competitive varieties were not distributed to specific companies. The low distribution rate may also be due to the company winning the bid in the collection, but the actual sales volume at hospitals was low. A delivery rate that is too low may affect the company's credit evaluation, etc., which will further affect the company's eligibility for future collection. However, the delivery rate is a multi-dimensional assessment. On the one hand, it is the hospital's satisfaction rate, and on the other hand, it also takes time efficiency into consideration.
Regarding the collection of proprietary Chinese medicines, Ren Fengbo told the Financial Federation reporter: “The company will participate in the collection of Guanxin Ning injections in 2023. In the future, products such as safflower injection, Qingkailing injection, and Chai Hu injection will also actively participate in accordance with the country's collection policy.” At the same time, it believes that with the loosening of collection policies for traditional Chinese medicine injections in hierarchical hospitals, the above products may all have a chance of benefiting in the future.
On August 7, 2023, Yabao Pharmaceutical announced that the company signed a technology transfer agreement with Shanxi University for a new traditional Chinese medicine project to receive clinical trial approvals, patents and related technical data for Class 6.1 (current classification category 1.1) “Chaigui Granules” owned by Shanxi University for 26 million yuan.
During the results meeting, Ren Pengbo revealed to the Financial Federation reporter that the company's innovative traditional Chinese medicine, Chai Gui granules, to treat depression, have completed IIa clinical trials and are undergoing clinical summaries.
Meanwhile, Yabao Pharmaceutical's innovative drug research and development also suffered a setback. On January 3, Yabao Pharmaceutical announced that the company decided to suspend clinical research and development work on aglatin hydrochloride capsules and API research and development projects, and capitalize the project's R&D amount of 579.66 million yuan in full to prepare for asset impairment.
Some investors asked, “The company spent tens of millions of dollars in vain to develop medicines for diabetes, so what stopped it?” In response, Ren Wuxian, chairman of Yabao Pharmaceutical, said, “Innovative drug development is risky, with a success rate of only about 10%... When innovative drugs encounter efficacy or safety issues in clinical practice, trials will be suspended or terminated.”
